Patents by Inventor Kelly Ann Swinney

Kelly Ann Swinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
    Patent number: 10231932
    Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: March 19, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kelly Ann Swinney, Patricia Nell Hurter, David E. Nadig, David Smith, Vance Hayden Thomas, Martin Paul Warman
  • PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
    Publication number: 20160354316
    Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: October 31, 2014
    Publication date: December 8, 2016
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kelly Ann SWINNEY, Patricia Nell HUNTER, David E. NADIG, David SMITH, Vance Hayden THOMAS, Martin Paul WARMAN
  • Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
    Patent number: 8716282
    Abstract: The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Joaquin Pastor-Fernández, José Manuel Bartolomé-Nebreda, Gregor James Macdonald, Susana Conde-Ceide, Óscar Delgado-González, Greta Constantia Peter Vanhoof, Michiel Luc Maria Van Gool, María Luz Martín-Martín, Sergio-Alvar Alonso-de Diego, Kelly Ann Swinney, Carina Leys, Johan Erwin Edmond Weerts, Stijn Wuyts
  • Polymorphic forms of a macrocyclic inhibitor of HCV
    Patent number: 8143402
    Abstract: Provided are crystalline forms of the compound of formula (I), which is a macrocyclic inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: March 27, 2012
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Sigrid Carl Maria Stokbroekx, Carina Leys, Kelly Ann Swinney, Stijn Wuyts, Andras Horvath
  • IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
    Publication number: 20110269752
    Abstract: The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.
    Type: Application
    Filed: April 28, 2011
    Publication date: November 3, 2011
    Inventors: Joaquin Pastor-Fernández, José Manuel Bartolomé-Nebreda, Gregor James Macdonald, Susana Conde-Ceide, Óscar Delgado-González, Greta Constantia Peter Vanhoof, Michiel Luc Maria Van Gool, María Luz Martin-Martín, Sergio-Alvar Alonso-de Diego, Kelly Ann Swinney, Carina Leys, Johan Erwin Edmond Weerts, Stijn Wuyts
  • POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV
    Publication number: 20100029715
    Abstract: Provided are crystalline forms of the compound of formula (I), which is a macrocyclic inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.
    Type: Application
    Filed: February 1, 2008
    Publication date: February 4, 2010
    Inventors: Sigrid Carl Maria Stokbroekx, Carina Leys, Kelly Ann Swinney, Stijn Wuyts, Andras Horvath